
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>



































• Useful for cell-based CD155 binding assay
• Useful as CD155-expressing target cells in reporter gene assay


Expression analysis of human CD155 on Raji/Human CD155 Stable Cell by FACS.
Raji/Human CD155 Stable Cell Line or negative control cell were stained with PE-labeled anti-Human CD155 antibody.

Blocking activity of anti-human TIGIT antibody.
This Raji/Human CD155 Stable Cell Line was incubated with serial dilutions of antibodies in the presence of reporter cells expressing human TIGIT. The EC50 of anti-human TIGIT antibody was approximately 2.05 μg/mL.

Passage stability analysis of receptors expression by FACS.
Flow cytometry surface staining of human CD155 on Raji/Human CD155 Stable Cell Line demonstrates consistent mean fluorescent intensity across passage 5-28.
Please contact us if you are interested in related cell pool service.
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Lerapolturev | Phase 2 Clinical | National Cancer Institute, Istari Oncology Inc, Duke University Medical Center | Ependymoma; Medulloblastoma; Solid tumours; Glioblastoma; Oligodendroglioma; Urinary Bladder Neoplasms; Brain Neoplasms; Breast Neoplasms; Astrocytoma; Gliosarcoma; Glioma; Carcinoma, Embryonal; Melanoma | Details | |
| NTX-1088 | Phase 1 Clinical | Nectin Therapeutics Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.




